Patent Expiry

Patent/Exclusivity Expiry: DEXTENZA

Other upcoming events for OCUL

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, 3-Arm Parallel Group Study to Evaluate the Effica
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and
Phase 3 ReadoutPhase 3 Topline: A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OT

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: DEXTENZA — OCUL Patent Expiry | BioSniper